Impact of accelerating booster vaccination amidst Omicron surge in the United States
Sah, P.; Nogueira Vilches, T.; Moghadas, S. M.; Fitzpatrick, M. C.; Schneider, E. C.; Galvani, A. P.
Show abstract
COVID-19 infections driven by the Omicron variant are sweeping across the United States. Although early evidence suggests that the Omicron variant may cause less severe disease than previous variants, the explosive spread of infections threatens to drive hospitalizations and deaths to unprecedented high levels, swamping already overburdened hospitals. Booster vaccination appears to be effective at preventing severe illness and hospitalization. However, the pace of booster vaccination in the US has been slow despite the available infrastructure to administer doses at a much higher rate. We used an age-stratified, multi-variant agent-based model to project the reduction in COVID-related deaths and hospitalizations that could be achieved by accelerating the current daily pace of booster vaccination in the US. We found that doubling the rate of booster vaccination would prevent over 400,000 hospitalizations and 48,000 deaths. Tripling the booster vaccination rate would avert over 600,000 hospitalizations and save 70,000 lives during the first four months of 2022.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Optimizing vaccine allocation for COVID-19 vaccines: potential role of single-dose vaccination 93%
- Behaviour, booster vaccines and waning immunity: modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era 93%
- Estimating the potential impact and diagnostic requirements for SARS-CoV-2 test-and-treat programs 93%
Similar papers in this journal
- Changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States between December 2021 and November 2022 95%
- Burden of lower respiratory tract infections preventable by adult immunization with 15- and 20-valent pneumococcal conjugate vaccines in the United States 94%
- Population immunity to SARS-CoV-2 in US states and counties due to infection and vaccination, January 2020-November 2021 94%
Similar papers in this journal
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.